Across TCGA pan-cancer cohorts, CIB1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CIB1 data layer compared with 28 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher CIB1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CIB1 expression acts as an unfavorable survival marker.

SCLC and PRAD are the cancer types where CIB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.055	0.708	<.001	12	view →
PRAD	DFS	Median	All	0.076	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: CIB1 tumor-vs-normal RNA expression · all CIB1 data types